Acessa Health Expands Leadership Team with Key Executive Hires

AUSTIN, Texas–(BUSINESS WIRE)–Acessa Health Inc., developer of the Acessa System®, a comprehensive, minimally invasive treatment for uterine fibroids, today announced the company has strengthened its existing leadership team through the appointment of three experts in medical device and healthcare business operations. Ryan Graver has joined the company as vice president, market access and reimbursement; Kathleen Malaspina has been named chief innovation officer and vice president of marketing; and Brian Bergeron, has been appointed chief technology officer and vice president of operations.
“Ryan, Kathleen and Brian bring vital expertise to Acessa Health at an exciting time for the company, as we recently announced Medicaid programs adding 20 million more female covered lives to our Acessa procedure,” said Kim Rodriguez, president and chief operating officer of Acessa Health. “Our expanded team is poised to drive the clinical and commercial expansion of the Acessa procedure, fulfilling our mission to improve the standard of care for women who seek uterine-sparing solutions for uterine fibroids.”Market access expert Ryan Graver brings to the company more than two decades of diverse healthcare experience spanning care delivery, research, business development and strategy, consulting, payer policy, market access and healthcare economics. Before joining Acessa, Mr. Graver served as president of MedAxiom, where he led national strategic initiatives with more than forty industry partners spanning pharma, medtech, health IT and numerous health-related service organizations. Prior to that, he held a global leadership role with Zimmer; directed U.S. healthcare economics and reimbursement for St. Jude Medical; and held multiple positions in major health systems. Mr. Graver received his MPH in healthcare administration and pharmaceutical economics and a BA in communication and health policy from the University of Arizona.Seasoned marketing executive Kathleen Malaspina has over 25 years of international business experience, primarily in the consumer healthcare, medical device and technology sectors. She joins Acessa after filling the same role at OrthoAccel Technologies, Inc., an innovative Houston-based start-up ranked one of the fastest-growing companies in North America for the past three years. Previously, Ms. Malaspina held international operational management positions with Motorola, Sanyo and Philips. While global marketing director at Philips, she was instrumental in the development and growth of the Sonicare brand. Later, as president of Malaspina Healthcare Consulting, Inc., she created business growth strategies for clients such as LivaNova (previously Cyberonics) and Cardiac Science. Ms. Malaspina earned her BA at University of Pittsburgh and an International MBA from IESE Business School in Barcelona, Spain.

Experienced medical device development, manufacturing and operations executive Brian Bergeron has held senior leadership positions at Fortune 500 companies such as Boston Scientific and Abbott Laboratories. He was also a founder of two start-up companies, Genesys Orthopedics and Auspine, where he specialized in executing launch strategies for new medical technologies and became deeply involved in leading the development and commercialization of multiple diagnostic and implantable technologies. Mr. Bergeron earned a BS in mechanical engineering from Worcester Polytechnic Institute and holds an MS in engineering management from the University of Texas at Austin.

About the Acessa System

The Acessa System is the only radiofrequency ablation system cleared by the U.S. Food and Drug Administration for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. It has been the subject of 21 peer-reviewed publications across 750 study patients. In January 2017, the American Medical Association (AMA) issued a new Category 1 CPT code specifically for Laparoscopic Radiofrequency (RF) Ablation of Uterine Fibroids, paving the way for the Acessa procedure to become the standard of care for as many as 70 million women in the United States. For more information, visit AcessaProcedure.com.

About Acessa Health Inc.

Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. Founded by gynecologist Dr. Bruce Lee, a pioneer in treating fibroid tumors, Acessa Health introduced the use of radiofrequency ablation for the treatment of uterine fibroids and is continuing to develop technologies that will improve the lives of patients with uterine fibroids. Acessa Health’s headquarters is located in Austin, Texas.

Contacts

Nobles Global Communications
Diana Soltesz, 818- 618-5634
diana@noblesgc.com

For International Women’s Day, Dallas Physician is Committed to Offering Women More Options…

It’s very important for women to take charge of their own health and know exactly what is going with their bodies. However, many women suffer in silence with uterine fibroids.

Jessica Shepherd, MD, MBA, a minimally invasive gynecologic surgeon at Baylor University Medical Center at Dallas, explains that uterine fibroids (myomas or leiomyomas) are tumors within the uterus that are the most common benign tumor of the pelvis. Fibroids can be various sizes that can range from the size of a grape to the size of a cantaloupe. In addition, they are also the leading indication for hysterectomies in the USA, where roughly 600,000 of these surgeries are performed per year. According to Dr. Shepherd, “there are so many other options for fibroids that as a physician, I feel it is my responsibility to counsel women. I have met so many women in their journey with fibroids that need reassurance and also a broader discussion on what they can do.”

Uterine fibroids have been show to impact between 70% and 80% of women before the age of 50 with severe symptoms occurring up to 30% of these patients. Symptoms include heavy menstrual bleeding, pelvic pressure and pain, painful intercourse and abdominal bloating depending on size and location of each fibroid. Fibroids can also affect fertility and in women who have fertility issues due to fibroids, they need options that will preserve the uterus so they can have pregnancies in the future.

Healthcare providers are able to offer various treatment options to address the symptoms that are presented from medical therapies, to minimally invasive gynecological procedures, such as the Acessa Procedure, up to and including major surgeries. The most important part of treating fibroids is that every patient’s journey is different, and every patient is looking for different outcomes. The results of treatments can vary depending on the age of the woman, severity of symptoms, the reproductive desire of the patient and the duration of their symptoms. In light of International Women’s Day, Dr. Shepherd is committed to #pressforprogress, and offer her patients the most comprehensive treatment options available.